Research Why Revolution Medicines May Be Big Pharma’s Next Takeover TargetBy Healthcare Propulsion StaffAugust 12, 20260 Quick Read RVMD has surged 492% over one year on daraxonrasib’s landmark pancreatic cancer data showing 13.2 versus 6.7 months…
